1. Introduction
The coronavirus disease of 2019 (COVID-19) epidemic has widely spread worldwide and led to more than 0.66 billion confirmed patients and about 6.7 million deaths up to September 2022 [
1]. To control the epidemic, various policies and measures have been implemented, such as implementing a lockdown policy [
2], keeping social distance to reduce the infection rate [
3], developing various COVID-19 vaccines to help protect the uninfected people [
4], isolating the suspected or confirmed individuals [
5], treating infected patients in dedicated emergency hospitals [
6], and conducting large-scale COVID-19 nucleic acid testing (NAT) to screen the infected individuals [
7]. In the early stage of the COVID-19 epidemic, many countries implemented the lockdown policy, which helped control the severe outbreak of the epidemic at the high price of socioeconomic damage. For example, in India, about 1.3 billion people were severely influenced by the lockdown, and many of them lost jobs [
8], and the U.S. lost about USD 65.3 billion a month during lockdown [
9]. To unlock people and recover social activity, it is important to quickly identify and cut off the transmission chain of the COVID-19 epidemic, especially in densely populated cities, and this requires conducting large-scale COVID-19 NATs effectively in post-lockdown years [
10].
Severe epidemics can be effectively controlled with the help of large-scale NATs [
11] since large-scale NATs not only allow earlier identification of asymptomatic and presymptomatic carriers [
12] but also help dynamically monitor the prevalence of the virus in the population across various areas [
13]. Many countries have implemented large-scale COVID-19 NATs. For example, a repeated nationwide NAT was conducted in Slovakia in November 2020 [
14]; Luxembourg conducted an NAT to cover everyone in May 2020 [
15]; a citywide NAT was launched in Liverpool, U.K. [
16]. More recently, Chengdu, a megacity located in southwestern China, implemented a large-scale NAT, which tests 20 million residents each day, to completely stop the spread of COVID-19 in two weeks. In practice, large-scale COVID-19 NATs can be conducted in two ways, i.e., at-home tests and centralized tests. Compared with the at-home tests, centralized tests can benefit from a group testing strategy (i.e., combining samples from multiple individuals into a single pool to test) and enhance the effectiveness and efficiency of large-scale COVID-19 NATs [
17,
18]. However, even with the group testing strategy, the costs of large-scale COVID-19 NATs can be still very high due to the overwhelming testing demands. For example, China finished 11.5 billion nucleic acid tests till April 2022 [
19], and the U.S. conducted 2 million NATs each week till May 2020 [
20]. Considering that new epidemics or new waves of the COVID-19 epidemic may appear in the near future and that the cost associated with large-scale NATs can be very high, planning and implementing large-scale NATs effectively and efficiently is vital to reducing the large-scale NAT cost and improving the preparedness and responses to potential large-scale epidemics in the future.
The effectiveness and efficiency of large-scale NATs can be improved in several ways, such as optimizing the supply network for NAT kits [
21], optimizing the service area of NAT facilities [
22], and optimizing the deployment of NAT sites [
23], which is the focus of this study. In practice, various types of NAT sites, as shown in
Figure 1, are deployed worldwide to serve the target populations who need testing. Specifically, in the U.S., some community-based testing sites and point-of-care facilities are deployed at some pharmacies, health centers, physician offices, urgent care facilities, temporary locations, etc., to conduct large-scale COVID-19 NATs [
24,
25]. In the U.K., the NAT sites are mainly deployed at clinics, pharmacies, and healthcare centers [
26]. In China, the NAT sites are mainly deployed at hospitals, clinics, pharmacies, and other temporary sites along the main streets.
The numbers and locations of the deployed NAT sites can influence the accessibility and expenditure of NATs significantly, and various types of medical resources, e.g., staff and medical supplies, are needed to run a deployed NAT site. Specifically, NAT accessibility can be improved by setting up 15 min NAT circles with a reasonable budget [
30]. Our field survey indicates that a deployed NAT site requires medical supplies such as protective suits, marks, and swabs, and is generally operated by several testing units (each testing unit has 3–5 staff to test, distribute the testing cotton swabs, record the personal information, and keep order and security). If few people are expected to show up at a testing site in a period, that site can be temporarily closed to reduce the cost of NATs without sacrificing service accessibility. However, in most practices, the NAT sites are statically deployed in all periods, which can lead to serious supply–demand imbalance (testing capacity overflow or waste) problems in some periods. To tackle these practical problems, a dynamic testing site deployment strategy should be implemented to generate more flexible NAT site deployment plans.
This study aims to optimize the large-scale nucleic acid testing with a dynamic testing site deployment strategy, and we propose a multiperiod location-allocation model, which explicitly considers the spatial–temporal distribution of the testing population and the time-varied availability of various testing resources. Our main contributions are threefold: first, we develop a multiperiod location-allocation model following a dynamic site deployment strategy to facilitate large-scale NATs considering the limitation of multitype medical resources and the movement of demands to the nearest deployed NATs; second, we investigate various static NAT site deployment strategies to show outperformance of the dynamic strategy and to generate theoretical insights; third, we conduct a real-world case study on Chengdu, China, to verify the effectiveness of our proposed model and to obtain managerial insights for better field practice of large-scale NATs.
The rest of the article is organized into four sections.
Section 2 reviews relevant studies.
Section 3 formally describes the problem and presents our multiperiod location-allocation model.
Section 4 conducts a case study to obtain managerial insights.
Section 5 draws the conclusions and discusses future work briefly.
2. Literature Review
Our literature review mainly covers location planning studies on non-emergency and emergency healthcare facilities (EHFs). While non-emergency healthcare facility planning studies pave a solid foundation for our study, the studies on EHFs, which are more closely related to ours since NAT sites are an example of EHFs, help point out the research gap.
In the literature, the location planning problems of various healthcare facilities such as community hospitals, medical healthcare centers, and drugstores are widely studied [
31]. In the early studies, the regional healthcare demands are assumed to be deterministic, and classic location planning models, such as the
p-median model, maximum covering model, and set covering model, are employed to optimize the locations of long-term care facilities [
32], perinatal facilities [
33], community health centers [
34], and blood banks [
35]. Moreover, multiperiod situations are considered in the location planning of healthcare facilities for nomadic dwellers who experience a seasonal movement [
36]. Uncertainties related to the healthcare facility locations, such as the stochastic demands for hospitals [
37] and the uncertain demands and transportation cost in a medical services network [
38,
39], are also addressed.
As the occurrence of various disasters, such as earthquakes, floods, hurricanes, mass-casualty incidences, and epidemics, becomes increasingly more frequent in the past two decades, the location planning problems related to the deployment of EHFs attract lots of research efforts. In general, the EHFs can be categorized as permanent and temporary facilities. The deployment of permanent EHFs, such as ambulance stations [
40,
41], emergency centers [
42], and trauma centers [
43], are optimized with the goals of covering demands effectively and providing emergency medical services efficiently. Specifically, Cho et al. [
44] optimized the locations of trauma centers, associated helicopter platforms, and helicopter depots simultaneously. Chan et al. [
45] investigated the problem of deploying the public automated external defibrillators and developed a general optimization framework for three situations. Based on real data from an emergency medical service system, Nasrollahzadeh et al. [
46] built a model to develop high-quality solutions for real-time ambulance dispatching and relocation management. Besides the permanent EHFs deployed for general emergency medical service, some other permanent EHFs are deployed before various disasters considering uncertain disaster impacts. For example, Mete and Zabinsky [
47] proposed a two-stage stochastic programming model to optimize the location and inventory level of medical supply before disasters and the supply distribution after disasters. Jenkins et al. [
48] proposed a robust location-allocation model to tackle a medical evacuation problem, which determines the locations of mobile aeromedical staging facilities and allocations of aeromedical helicopters for military operations.
Temporary emergency healthcare facilities are significant to increase the limited capacity of emergency medical services and serve victims better during and after disasters [
49]. The existing studies investigate the deployment of various temporary EHFs, including temporary emergency medical centers [
50,
51], alternative care sites [
52], points of dispensing [
53], and NAT sites [
23]. Specifically, Chen and Yu [
54] optimized the locations of temporary emergency medical service facilities considering the existing hospitals and transportation infrastructure in post-disaster responses. Sharma et al. [
55] proposed a location-allocation model for dynamically deploying temporary blood banks during and after disasters. Tang et al. [
56] developed a multiperiod vaccination planning model to optimize the opening and closing of vaccine sites in various periods. Luo et al. [
57] built a multiperiod location-allocation model for deploying emergency healthcare facilities and managing various types of patients integrally during COVID-19 epidemics. Some other studies focus on the deployment of COVID-19 NAT laboratories. Devi et al. [
58] proposed a location-allocation model to deploy temporary testing laboratories for surging susceptible and infected individuals in India. Hosseini-Motlagh et al. [
21] further considered the location planning of mobile testing labs in developing a supply network for COVID-19 NAT kits. On the contrary, to the best of our knowledge, the studies on the deployment or locations of NAT sites are rather limited. Fan and Xie [
22] addressed a territory design problem, which optimizes the service area of each NAT facility and considers purchasing insufficient resources from third-party medical institutions at high prices. Risanger et al. [
59] optimized the selection of pharmacies for COVID-19 testing with a goal of maximizing the size of the population who travel to their nearest selected pharmacy. Villicana-Cervantes and Ibarra-Rojas [
60] planned locations of COVID-19 testing labs considering several facility accessibility indicators and the service areas of labs. Both [
59] and [
60] were based on the
p-center location model, and they limited the maximum number of testing facilities and ignored constraints related to the service capacity, medical supplies, and testing staff and the fixed cost of facility deployment. In particular, Liu et al. [
23] focused on optimizing the locations and the time-varied supply capacities of NAT facilities, which are similar to test kit warehouses and delivery test kits to the demand points in each period. Although the studies of [
23] and ours both focus on the dynamic management of NAT facilities, the facilities themselves are different, and our NAT sites can be viewed as the demand points in [
23].
In sum, our literature review points out two research gaps. First, although many previous works contribute to controlling the COVID-19 epidemic, few studies focus on enhancing the NAT operation, especially via optimizing the NAT site deployment. Second, the travel cost associated with the target population, who has a dynamically changed spatial–temporal distribution and normally self-move to their nearest emergency medical facility in each period, is seldom considered. To fill the gaps, we tackle the NAT site deployment problem, which explicitly considers the time-varied spatial–temporal distribution of the target population and the time-varied availability of various testing resources in this study.
3. Problem Statement and Model Formulation
We illustrate our dynamic site deployment problem with
Figure 2. As illustrated by the green squares with different shades (the deeper shade, the more population), the spatial distributions of the population in a city are time-varying, which can be due to that on weekdays, people attend work downtown in the morning and return home at residential areas at night. Due to the time-varied population distribution, the COVID-19 NAT demands (denoted with red circles) also vary in time and space, and this motivates a dynamic site deployment strategy, which dynamically opens and closes the candidate COVID-19 NAT sites, to be implemented for better supply–demand balance. Based on field practices, we assume that the target people self-move to their nearest deployed testing sites (shown by the yellow arrows) in each period, and we aim to optimize the dynamic NAT sites deployment plan under a cost-minimization goal.
We consider a planning horizon, which includes periods, and we contain all periods in a set T, i.e., . We let all demand points and all candidate NAT sites be contained in sets I and J, respectively. Moreover, various types of medical supplies and staff, which are important for the COVID-19 NAT, form sets K and H, respectively. Due to the movement of the target population, the demand amount varies in time and space, and we let be the demand amount at demand point in period . We denote the distance between each demand point to each candidate NAT site as . Moreover, for each candidate NAT site , we denote its testing capacity (the maximum amount of demand that can be served) per period, deployment cost, and unit penalty costs of capacity waste (overflow) as , , and (), respectively. To run an NAT site for one period, amount of types medical supplies and number of type staff are required. As the emergency medical resources for large-scale COVID-19 NAT are relatively limited and time-varied, we denote the total amount (number) of type medical supplies (type staff) available in period as (). Finally, to measure the accessibility, we let be a factor transferring people’s walking distance into cost, and denote M as a huge positive number.
The key decisions of dynamically opening NAT sites are denoted with binary decision variables, , which is 1 if candidate NAT site opens in period , and is 0 otherwise. Since we assume that the target population of each demand point will self-move to the nearest opened NAT site, the site location decisions () will also determine the spatial allocation of demands to the opened sites in each period. Thus, we define auxiliary variables to evaluate the number of target people of demand point that self-move to candidate NAT site in period . Moreover, due to the spatial–temporal variation of demands, the capacity of opened NAT sites can be left or exceeded. Thus, we employ and to evaluate the amount of left capacity and the amount of exceeded capacity at candidate NAT site in period .
The notations of sets, parameters, and decision variables are summarized in
Table 1.
With the above notations, the multiperiod location-allocation Model (P) is formulated as follows:
The objective function (1) minimizes the total cost of COVID-19 NAT for all periods, which includes the NAT site deployment cost (the first term), the penalty costs related to the testing capacity waste (the second term) and overflow (the third term), and the weighted travel cost of all target populations (the last term). Specifically, the NAT site deployment cost is incurred by setting up the facility, e.g., preparing testing supplies and dispatching staff. The testing capacity waste and overflow penalty costs are due to the imbalance between the dynamic testing demand and the prepared testing capacity. When the testing demand is lower (higher) than the prepared testing capacity, a capacity waste (overflow) penalty is caused. The weighted travel cost evaluates the NAT service accessibility of the target population, and we assume that the travel cost is proportional to the distance.
Constraints () ensure that in each period t, all target populations of each demand point i will self-move to an NAT site j. Constraints () and () together enforce that the target populations of each demand point will self-move to their nearest opened COVID-19 NAT site in each period. Constraints () and () limit the maximum amount of supply and the maximum number of staff available for deploying NAT sites in each period, respectively. Constraints () and () are flow balance constraints at each candidate NAT site for periods 2 to and period 1, respectively. Constraints () ensure that if there is an overflow at an NAT site in period t, then that site must be deployed in period as well. Constraints ()–() set bounds for the binary and non-negative continuous decision variables.
To show the benefits of the dynamic site deployment strategy, we compare the dynamic site deployment strategy with the real deployment plan implemented in practices and other static strategies, which keep the site deployment unchanged for all periods. We denote the dynamic site deployment strategy as the base strategy (BS) and let the real plan be Comparison Strategy I (CS-I). We denote a static strategy, which obtains a static site deployment plan based on the time-averaged demands of all periods, as Comparison Strategy II (CS-II), and CS-II leads to the following static (single-period) Model (SP):
where
,
, and
, are the time-averaged values of
,
and
, respectively, and the static version of the dynamic decision variables
,
,
, and
are denoted with a hat, correspondingly. Moreover, we consider Comparison Strategy III (CS-III), which produces a static deployment plan by ensuring that the site deployment plan is unchanged in each period, and it is produced by Model (TP), which is equivalent to adding extra constraints
to Model (P).
There exist some properties for the above three strategies BS, CS-II, and CS-III, and the corresponding Models (P), (SP), and (TP).
Lemma 1. With Constraint (25), Constraints (5) and (6) are tighter than Constraints (18) and (19), respectively. Proof. With Constraint (
25), the resource constraints of (TP) are equivalent to
and
. As
and
, the lemma is thus proved. □
Proposition 1. (a) Any feasible solution of Model (TP) is feasible to Model (P).
(b) Any feasible solution of Model (TP) can induce a feasible solution to Model (SP).
(c) A feasible solution of Model (SP) may not be a feasible solution to Model (P) with Constraint (25) added. Proof. (a) is obvious and (c) is the direct corollary of Lemma 1. We only prove (b). For (b), we declare that if is a feasible solution of Model (TP), then there exists a solution feasible to Model (SP), where . With Lemma 1 we know that is feasible to Constraints () and (), and with given values of there is a unique group of values of to other constraints of Model (SP) since the values of and are flexible and M is big enough for to satisfy demands . Consequently, (b) is proved. □
Proposition 1 indicates that the plan given by CS-II may not fit for the real situation as BS defines, except that the resources are abundant, whereas CS-III always produces a feasible plan for the real situation. This proposition also implies that the decision-maker can obtain feasible plans with CS-II and CS-III, as it takes much less time to solve Models (SP) and (TP) than to solve Model (P), especially for large-scale problem instances.
5. Conclusions and Future Work
In this study, we propose a multiperiod location-allocation model, which implements a dynamic site deployment strategy, to facilitate the COVID-19 NAT site deployment for COVID-19 control. With a real-world case study, which is based on the Chenghua district of Chengdu, China, we verify the effectiveness and benefits of our proposed model and obtain various managerial insights. For example, deploying NAS sites with the spatial distribution of population has a significant effect on cost reduction, and moving large-scale COVID-19 nucleic acid testing out of general hospitals and utilizing testing sites with small or medium service capacity can contribute to better field practices. Our study emphasizes the importance of deploying NAT sites dynamically for better field practices and reveals that (1) the optimal plan of the dynamic testing site deployment strategy is more flexible and reliable to serve the time-varied testing demands, (2) dynamically deploying NAT sites can help reduce the testing cost and increase the robustness of producing feasible plans with limited medical resources, and (3) decision-makers can obtain various NAT site deployment plans by adjusting the importance of service accessibility.
In the future, several issues related to large-scale COVID-19 NAT can be investigated further. First, a systematic simulation study can be conducted to incorporate more NAT details and justify the real-world applicability of our model. Second, the stochasticity of NAT demand in each period can be further addressed by building a multistage stochastic programming model. Third, various types of testing demands, which can have different infection risks and testing requirements, can be considered to reduce potential cross-infection risks during testing. Fourth, the coordination and cooperation of multiple districts or cities can be investigated to enhance COVID-19 NAT on a greater scale.